Cargando…
HDAC inhibition prevents transgene expression downregulation and loss-of-function in T-cell-receptor-transduced T cells
T cells that are gene-modified with tumor-specific T cell receptors are a promising treatment for metastatic melanoma patients. In a clinical trial, we treated seven metastatic melanoma patients with autologous T cells transduced to express a tyrosinase-reactive T cell receptor (TCR) (TIL 1383I) and...
Autores principales: | Moore, Tamson V., Scurti, Gina M., DeJong, Matthew, Wang, Siao-Yi, Dalheim, Annika V., Wagner, Courtney R., Hutchens, Kelli A., Speiser, Jodi J., Godellas, Constantine V., Fountain, Chris, Fleser, Jessica, Moudgil, Tarsem, Thomas, Mallory, Murray, David, Curti, Brendan D., Clark, Joseph I., Fox, Bernard A., Nishimura, Michael I. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Gene & Cell Therapy
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7878989/ https://www.ncbi.nlm.nih.gov/pubmed/33614916 http://dx.doi.org/10.1016/j.omto.2021.01.014 |
Ejemplares similares
-
Melanoma reactive TCR-modified T cells generated without activation retain a less differentiated phenotype and mediate a superior in vivo response
por: Wang, Siao-Yi, et al.
Publicado: (2021) -
A Rare Collision in Dermatopathology: Basal Cell Carcinoma and Atypical Fibroxanthoma
por: Speiser, Jodi J., et al.
Publicado: (2015) -
The transfer of genetically engineered lymphocytes in melanoma patients: a Phase I dose escalation study
por: Regan, Courtney, et al.
Publicado: (2015) -
Improved MHC II epitope prediction — a step towards personalized medicine
por: Moore, Tamson V., et al.
Publicado: (2019) -
Genetically engineered lymphocytes in metastatic melanoma: TIL 1383I TCR transduced T-cells are detectable after infusion
por: Regan, Courtney, et al.
Publicado: (2013)